![CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction - ScienceDirect CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0065277605880010-gr2.jpg)
CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction - ScienceDirect
![CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction - ScienceDirect CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0065277605880010-gr5.jpg)
CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction - ScienceDirect
![CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial | Nature Medicine CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial | Nature Medicine
![Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells - ScienceDirect Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2319417019304810-gr4.jpg)
Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells - ScienceDirect
![The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease | Nature Reviews Rheumatology The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease | Nature Reviews Rheumatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnrrheum.2014.54/MediaObjects/41584_2014_Article_BFnrrheum201454_Fig1_HTML.jpg)
The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease | Nature Reviews Rheumatology
![File:Schematic representation of the CD22 and B-cell receptor signalling process.png - Wikimedia Commons File:Schematic representation of the CD22 and B-cell receptor signalling process.png - Wikimedia Commons](https://upload.wikimedia.org/wikipedia/commons/d/d3/Schematic_representation_of_the_CD22_and_B-cell_receptor_signalling_process.png)
File:Schematic representation of the CD22 and B-cell receptor signalling process.png - Wikimedia Commons
![Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models | Science Translational Medicine Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.abc6401/asset/66a1288a-faa5-4f7c-8c34-872fd80694d0/assets/graphic/abc6401-f1.jpeg)
Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models | Science Translational Medicine
![The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus - ScienceDirect The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1568997215001627-fx1.jpg)
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus - ScienceDirect
![CD22 und CD72 sind in B‑Lymphozyten dominant exprimierte inhibitorische Rezeptoren und regulieren systemische Autoimmunerkrankungen | SpringerLink CD22 und CD72 sind in B‑Lymphozyten dominant exprimierte inhibitorische Rezeptoren und regulieren systemische Autoimmunerkrankungen | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00393-015-0038-2/MediaObjects/393_2015_38_Fig1_HTML.gif)
CD22 und CD72 sind in B‑Lymphozyten dominant exprimierte inhibitorische Rezeptoren und regulieren systemische Autoimmunerkrankungen | SpringerLink
![Heterogeneous Expression of CD19 and CD22 on B-ALL (A) CD19 and CD22... | Download Scientific Diagram Heterogeneous Expression of CD19 and CD22 on B-ALL (A) CD19 and CD22... | Download Scientific Diagram](https://www.researchgate.net/publication/328765607/figure/fig1/AS:707528530857986@1545699355807/Heterogeneous-Expression-of-CD19-and-CD22-on-B-ALL-A-CD19-and-CD22-expression-on.png)
Heterogeneous Expression of CD19 and CD22 on B-ALL (A) CD19 and CD22... | Download Scientific Diagram
![Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults](https://www.mdpi.com/cancers/cancers-12-00303/article_deploy/html/images/cancers-12-00303-g004.png)
Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
![Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults](https://www.mdpi.com/cancers/cancers-12-00303/article_deploy/html/images/cancers-12-00303-g003.png)
Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
![CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial | Nature Medicine CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01497-1/MediaObjects/41591_2021_1497_Fig1_HTML.png)
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial | Nature Medicine
Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis | ACS Chemical Biology
![Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults](https://www.mdpi.com/cancers/cancers-12-00303/article_deploy/html/images/cancers-12-00303-g001.png)
Cancers | Free Full-Text | CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
![CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies - ScienceDirect CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497122005122-grabsf1.jpg)